Skip to content
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
Menu
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Innovative Treatments for Liver & Pancreatic Tumors
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Platform
    • Drug Delivery Technology
  • Pipeline
    • Our Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • The Trisalus Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
Back to Leadership
  • OUR TEAM

Mats Wahlström

  • Chairman of the Board

Mats Wahlström has served as Chairman of the board of directors of TriSalus since January 2017. Mats has also served as the Co-Chairman of HW Investment Partners, LLC since July 2016 and as Partner and Executive Chairman of KMG Capital Partners, LLC since April 2012, both investment funds focused on investments in the healthcare industry.

In addition, Mats has served as the Chairman of the board of directors of Triomed AB since October 2016, as the lead independent director of Coherus Biosciences, Inc., a public biotech company, since January 2012 and as Chairman of Caduceus Medical Holdings, Inc. since August 2010. Mats has served on the boards of directors of Alteco Medical AB since October 2012, Circuit Clinical Solutions, Inc. since July 2016 and PCI | HealthDev since August 2010. He served as a director of Health Grades, Inc. a Nasdaq-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010, as a director of Getinge AB, a Swedish Stock Exchange-listed medical device company, from March 2012 to March 2017, and as a director of Zynex Inc. an over-the-counter medical device manufacturer, from October 2010 through January 2014. From January 2004 to December 2009, Mats served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG & Co. KGaA. From November 2002 to December 2009, Mats served as President and Chief Executive Officer of Fresenius Medical Services. Prior to that, Mats held various positions at Gambro AB in Sweden from January 1983 to February 2000, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare Inc. as well as Chief Financial Officer of the Gambro Group.

Mats has a B.S. degree in Economics and Business Administration from the University of Lund, Sweden.

© 2024 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL